ERBB2 and breast cancer: To determine whether naturally occurring FGFR1 amplification promotes resistance to fulvestrant plus CDK4/6 inhibitors, we selected three ER+/HER2− human breast cancer cell lines with FGFR1 gene amplification as determined by FISH: CAMA1, MDA-MB-134, and HC150015.